Effect of 35624® Alflorex® in Functional Gastrointestinal Disorders (FGIDs) in Children.
Open Label Clinical Trial on the Efficacy of a Probiotic Strain of Bifidobacterium Longum 35624 (Alflorex®) in Functional Gastrointestinal Disorders (GFRS) in Children 8 to 18 Years of Age.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kelly Seamans, PhD
- Phone Number: +353 879881389
- Email: ksea@novozymes.com
Study Locations
-
-
-
Santiago, Chile
- Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 8-18 years
- Any sex
- ROME IV diagnostic criteria Pediatric functional digestive disorders: in children and adolescents. H2. Functional abdominal pain disorders H2a. Functional dyspepsia H2b. Irritable bowel syndrome H2d. Functional abdominal pain not otherwise specified H3. Functional defecation disorders H3a. Functional constipation H3b. Non-retentive fecal incontinence Meet the criteria during the last three months with the onset symptoms for at least six months before diagnosis
- IBS rated moderate to severe according to GSRS-IBS score (Spanish / LA)
- At least two episodes of abdominal pain per week
- No consumption of probiotics at least two weeks before baseline measurements (but preferably four weeks);
- Dad, Mom, or Guardian able to understand the protocol;
- Be willing to maintain stable dietary habits throughout the study period;
- Be able to communicate well with the Investigator, to understand and comply with the requirements of the study and be judged suitable for the study in the opinion of the Investigator;
- Signature of Informed Consent.
Exclusion Criteria:
- Children with systemic, organic or metabolic diseases, immunosuppression, different from IBS
- Previous major abdominal surgery;
- Consumption of proton pump inhibitors, H2 antagonists;
- Consumption of probiotics in the two weeks before baseline measurements;
- Are less than 8 or older than 18 years of age at the time of consent;
- Subject who has been on antibiotics during the past 3 months;
- Subjects who have not had at least two episodes of abdominal pain per week;
- Subject with a malignant disease or any concomitant end-state organ disease and/or laboratory abnormalities considered by Investigators to be risky or that could interfere with data collection;
- Subject who are coeliac or lactose intolerant;
- Known allergy to any of the components of the test product;
- Participation in a clinical study with an investigational product within 60 days before screening, or plans to participate in another study during the study period;
- Subject has a history of non-compliance;
- Use of dietary supplements or other fermented foods that contain live bacteria.
- Pregnant or lactating females.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Probiotic
Alflorex® The participants consume one probiotic capsule a day for 12 weeks.
|
Each probiotic capsule contains 1 x 10^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in abdominal pain assessed by the Numeric Rating Scale for pain
Time Frame: Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain which goes from 0 (no pain) to 10 (worst pain)
|
Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
|
Change in IBS symptom severity assessed by an adapted Irritable Bowel Symptom Severity Scoring System (IBS-SSS)
Time Frame: Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
The IBS-SSS measures symptom severity in IBS patients and is a reliable and validated questionnaire taking into account the composite score of abdominal pain, number of days with abdominal pain, bloating/distention, satisfaction with bowel habits and IBS-related quality of life.
For this study, an adapted version was used in conjunction with the NRS-11 pain scale for the purposes of accurately capturing the response of a pediatric population.
The NRS-11 pain scale goes from 0-10 with 0 indicating "no pain" and 10 indicating "very severe pain."
|
Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in quality of life assessed by the Irritable Bowel Syndrome-Quality of Life questionnaire
Time Frame: Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
The IBS-QOL scoring is from 0 to 100, with higher scores indicating better IBS specific quality of life
|
Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
|
Change in stool consistency assessed using the Bristol Stool Form Scale
Time Frame: Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
The Bristol Stool Form Scale classifies stool according to shape and consistency and assigns a sample a number from 1-7 depending on its characteristics, corresponding to constipation normal or diarrhea.
|
Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
|
Change in stool frequency
Time Frame: Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
Assessed from patient diaries
|
Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
|
Change in days absent from school
Time Frame: Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
Assess from patient diaries
|
Change from baseline, assessed at 6 and 12 weeks of supplement intake
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Eileen Murphy, PhD, PrecisionBiotics Group Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PBCT002A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.